Intercept Pharmaceuticals: Q3 Earnings Insights

Shares of Intercept Pharmaceuticals ICPT rose 2.9% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 37.84% year over year to ($1.61), which beat the estimate of ($1.93).

Revenue of $79,521,000 higher by 28.36% from the same period last year, which beat the estimate of $78,630,000.

Looking Ahead

Intercept Pharmaceuticals hasn't issued any earnings guidance for the time being.

The upcoming fiscal year's revenue expected to be between $310,000,000 and $320,000,000.

Conference Call Details

Date: Nov 09, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/b3wvunam

Price Action

52-week high: $125.00

Company's 52-week low was at $27.02

Price action over last quarter: down 44.92%

Company Overview

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.